Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 15/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 9/20 | 0.58 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16295335 | 0.97 | KDM4E (0.71) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL16295274 | 0.83 | KDM4E (0.56) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL1177057 | 0.83 | KDM4E (1.00) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL1177499 | 0.83 | KDM4E (0.75) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL1177695 | 0.82 | KDM4E (0.69) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL4535360 | 0.81 | KDM4E (0.64) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL16294362 | 0.80 | KDM4E (0.70) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL6252358 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL17351540 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 | |
| SCHEMBL17351373 | 0.79 | KDM4E (0.97) | KDM4EALDH1A1ADORA2ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556831-A1 | 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine-6-carbonitriles as Adenosin Receptor Ligands for Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556856-A1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556856-A1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556831-A1 | 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine-6-carbonitriles as Adenosin Receptor Ligands for Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2234980-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080198-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080198-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | TNNI3, QDPR, RYR2 | KDM4E 3945/4885ALDH1A1 2826/4885ADORA2A 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.